Tandem Diabetes Care (NASDAQ:TNDM) Stock: Insider Christopher Twomey Sells 1,700 Shares

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Director Christopher Twomey sold 1,700 shares of Tandem Diabetes Care stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total transaction of $32,555.00. Following the completion of the transaction, the director directly owned 24,434 shares of the company’s stock, valued at approximately $467,911.10. This represents a 6.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tandem Diabetes Care Stock Down 3.4%

Shares of NASDAQ:TNDM opened at $19.11 on Friday. The company’s fifty day moving average is $18.02 and its two-hundred day moving average is $18.94. The company has a debt-to-equity ratio of 4.62, a quick ratio of 2.65 and a current ratio of 3.18. Tandem Diabetes Care, Inc. has a 1-year low of $12.26 and a 1-year high of $29.65. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -20.55 and a beta of 1.66.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, August 6th. The medical device company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.01. The business had revenue of $254.56 million during the quarter, compared to the consensus estimate of $254.99 million. Tandem Diabetes Care had a negative net margin of 6.08% and a negative return on equity of 45.97%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.78) EPS. Equities analysts anticipate that Tandem Diabetes Care, Inc. will post -0.66 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Tandem Diabetes Care in a report on Tuesday, September 8th. UBS Group began coverage on shares of Tandem Diabetes Care in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 target price for the company. Mizuho set a $18.00 price target on shares of Tandem Diabetes Care in a research note on Tuesday, October 13th. Canaccord Genuity Group set a $40.00 price target on Tandem Diabetes Care in a research note on Friday, August 7th. Finally, Oppenheimer restated an “outperform” rating on shares of Tandem Diabetes Care in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Tandem Diabetes Care has a consensus rating of “Hold” and an average price target of $27.08.

Institutional Investors Weigh In On Tandem Diabetes Care

Institutional investors have recently bought and sold shares of the business. First Light Asset Management LLC grew its holdings in shares of Tandem Diabetes Care by 157.4% during the 2nd quarter. First Light Asset Management LLC now owns 3,383,553 shares of the medical device company’s stock valued at $51,058,000 after acquiring an additional 2,068,838 shares in the last quarter. Defilade Capital Management L.P. bought a new stake in shares of Tandem Diabetes Care in the 1st quarter valued at approximately $14,606,000. Quantinno Capital Management LP increased its holdings in Tandem Diabetes Care by 123.5% in the first quarter. Quantinno Capital Management LP now owns 653,870 shares of the medical device company’s stock worth $12,535,000 after buying an additional 361,361 shares during the last quarter. First Trust Advisors LP bought a new position in Tandem Diabetes Care during the first quarter valued at approximately $6,570,000. Finally, Principal Financial Group Inc. grew its position in Tandem Diabetes Care by 2.2% in the first quarter. Principal Financial Group Inc. now owns 331,541 shares of the medical device company’s stock worth $6,356,000 after acquiring an additional 7,279 shares in the last quarter.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem’s product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.